Related Experiment Video

Updated: Jul 7, 2026

Magnetic Adjustment of Afterload in Engineered Heart Tissues
09:40

Magnetic Adjustment of Afterload in Engineered Heart Tissues

Published on: May 5, 2020

State-of-the-Art Prevention of Heart Failure: Maladaptive versus Adaptive Hypertrophy

Gianluigi Condorelli1, Michael Vg Latronico, Mario Condorelli

  • 1Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, California, USA, and I.R.C.C.S. MultiMedica, Milan, Italy.

Heart Failure Monitor
|February 15, 2008
PubMed

Insights

Cardiac hypertrophy, initially beneficial for normalizing heart stress, can lead to detrimental long-term effects and increased mortality. Understanding pathological hypertrophy is key to developing new heart failure therapies.

Area of Science:

  • Cardiology
  • Pathophysiology
  • Molecular Biology

Background:

  • Cardiac hypertrophy is the heart muscle's adaptive response to increased hemodynamic load.
  • While initially beneficial for normalizing ventricular wall stress, progressive hypertrophy carries significant long-term risks.

Purpose of the Study:

  • To review the events associated with cardiac hypertrophy.
  • To discuss strategies for preventing pathological hypertrophy.
  • To explore therapeutic approaches targeting hypertrophic growth.

Main Methods:

  • This is a review article, synthesizing existing research on cardiac hypertrophy.
  • It outlines the physiological and pathological processes involved.
  • It discusses potential preventative and therapeutic strategies.

Main Results:

  • Progressive cardiac hypertrophy is linked to increased mortality and heart failure.
  • Understanding the dual nature of hypertrophy (beneficial vs. deleterious) is crucial.
  • Novel therapeutic strategies could leverage beneficial aspects while mitigating harmful consequences.

Conclusions:

  • Pathological cardiac hypertrophy is a major contributor to heart failure, a leading cause of death.
  • Further research into the mechanisms of hypertrophy is essential for developing effective treatments.
  • Targeting hypertrophic pathways offers potential for improved cardiovascular outcomes.

More Related Videos

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Related Concept Videos

Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...